RedHill’s Experimental MS Therapy, RHB-104 (Combined Antibiotic Therapy), Receives Notice of Allowance on U.S. Patent

RHB-104, is a mixture of 3 antibioticsi (95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine), intended to be used along with interferon.  The good news in this, assuming it is effective and is commercialized effectively too, is that knowledge of MSi being caused by or excacerbated by a germ will likely come to be more widely recognized:

Link...

http://multiplesclerosisnewstoday.com/2016/02/12/redhill-biopharma-recei...<

Interesting stuff Tom and thanks for posting it.  It would be good if bacterial infectionsi that cause MSi were of a higher profile.  Irene 

Thank you for this

well it is just a patent. Does not mean anything. The only interesting thing will be the results of that phase iii trial. Otherwise more guff. A company survival/marketing advert in my opinion.

 

MMHHPP

RRMSi since 2010. Asthmai sufferer during  2008-2012 - Free of asthma since started  Wheldon protocol- october 2012 doxyi 200mg, Azytrom 3x week, NACi 1200g day and vitaminsi-  January 2013 started Flagyli pulses. i s

I agree with Irene about bacterial infectionsi and MSi, yet one of the mixtures here: clofazimine, worries me a bit: an anti-leprosy drug that can very quickly change the colour of your skin to pink or brown, and also give you severe depression, which has caused suicides: https://en.wikipedia.org/wiki/Clofazimine< ........................Sarah

Completed Stratton/Wheldon regime for aggressive secondary progressive MSi in June 2007, after four years, three of which intermittent.   Still improving bit by bit and no relapses since finishing treatment.

Comment viewing options

Select your preferred way to display the comments and click "Save settings" to activate your changes.